Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorpromazine Hydrochloride

FDA-approved product (concentrate, oral), marketed as Chlorpromazine Hydrochloride, Chlorpromazine Hydrochloride Intensol, Promapar and 2 more.

Registered studies
33
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chlorpromazine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Nausea and vomiting
  • Porphyria
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with aliphatic side-chain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli30.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis75.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

33registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorpromazine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorpromazine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

    NCT00202293 · start 2001-10-01

    Registered record
    Registry ID
    NCT00202293
    Conditions
    Bipolar Disorder; Schizoaffective Disorder
    Interventions
    Olanzapine; Lithium; Chlorpromazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-10-01
    Completion
    2015-11-01
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Schizoaffective Disorder
    InterventionOlanzapine; Lithium; Chlorpromazine
    PhasePhase 4
    Registry statusCompleted

  • How to Treat Opiate Withdrawal in Neonates

    NCT02810782 · start 2001-06

    Registered record
    Registry ID
    NCT02810782
    Conditions
    Neonatal Abstinence Syndrome
    Interventions
    Phenobarbital; Chlorpromazine; Morphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    2007-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Abstinence Syndrome
    InterventionPhenobarbital; Chlorpromazine; Morphine
    PhasePhase 3
    Registry statusCompleted

  • Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia

    NCT00169039 · start 1994-12

    Registered record
    Registry ID
    NCT00169039
    Conditions
    Schizophrenia
    Interventions
    Clozapine; Chlorpromazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    1994-12
    Completion
    2002-02
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionClozapine; Chlorpromazine
    PhasePhase 4
    Registry statusTerminated